Claims
- 1. A method for inhibiting the development of a hematological malignancy in a patient, comprising administering to a patient an effective amount of a polypeptide comprising at least an immunogenic portion of Her2/neu, or a polynucleotide encoding said polypeptide, wherein said hematological malignancy is selected from the group consisting of AML, CML, CLL, MDS, myelomas, Hodgkin lymphomas and non-Hodgkin lymphomas, and thereby inhibiting the development of the hematological malignancy in the patient.
- 2. The method of claim 1, wherein said immunogenic portion of Her2/neu comprises an amino acid sequence consisting essentially of SEQ ID NO: 3.
- 3. A method for inhibiting the development of a hematological malignancy in a patient, comprising administering to a patient an effective amount of antigen-presenting cells that express a polypeptide comprising at least an immunogenic portion of Her2/neu, wherein said hematological malignancy is selected from the group consisting of AML, CML, CLL, MDS, myelomas, Hodgkin lymphomas and non-Hodgkin lymphomas, and thereby inhibiting the development of the hematological malignancy in the patient.
- 4. The method of claim 3, wherein said immunogenic portion of Her2/neu comprises an amino acid sequence consisting essentially of SEQ ID NO: 3.
- 5. A method according to claim 3, wherein the antigen-presenting cells are dendritic cells.
- 6. A method for inhibiting the development of a hematological malignancy in a patient, comprising the steps of:
(a) incubating CD4+ and/or CD8+T cells isolated from a patient with at least one component selected from the group consisting of:
(i) a polypeptide comprising at least an immunogenic portion of Her2/neu; (ii) a polynucleotide encoding such a polypeptide; and (iii) an antigen-presenting cell that expresses such a polypeptide; such that T cells proliferate; and (b) administering to the patient an effective amount of the proliferated T cells, and thereby inhibiting the development of a hematological malignancy in the patient.
- 7. The method of claim 6, wherein said immunogenic portion of Her2/neu comprises an amino acid sequence consisting essentially of SEQ ID NO: 3.
- 8. A method according to claim 6, wherein the hematological malignancy is selected from the group consisting of AML, CML, CLL, MDS, myelomas, Hodgkin lymphomas and non-Hodgkin lymphomas.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a CIP of U.S. application Ser. No. 09/638,280, which is CIP of U.S. application Ser. No. 09/404,443, and is related to a PCT application filed Aug. 22, 2000.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09675904 |
Sep 2000 |
US |
Child |
10313644 |
Dec 2002 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09638280 |
Aug 2000 |
US |
Child |
09675904 |
Sep 2000 |
US |
Parent |
09404443 |
Sep 1999 |
US |
Child |
09638280 |
Aug 2000 |
US |